Latigo Biotherapeutics
PrivateLast Round
Series B
Mar 17, 2025
Total Funding Raised
$285M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Latigo Biotherapeutics is a biotechnology company developing innovative non-opioid pain medicines that target pain at its source to provide effective, rapid-acting relief without the risk of addiction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Latigo Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Latigo Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 17, 2025 | ||||
| Series A | Feb 14, 2024 |
Latigo Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Westlake Village BioPartners | Series B, Series A |
| Cormorant Asset Management | Series B |
| Corner Ventures | Series A |
| Blue Owl Capital | Series B |
| Deep Track Capital | Series B |
| 5AM Ventures | Series B, Series A |
| Foresite Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
Advancing non-opioid pain therapies with a Phase 3 asset.
- Mar 3, 2026
Neha Krishnamohan appointed as CFO and CBO.
Latigo Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Latigo Biotherapeutics's valuation, stock price, and market status.